Na tej stronie
01AORT cena
02Zrzut ekranu
03Wykres
04Podziały akcji
05O nas
06Wyniki
07Wycena i wskaźniki
13Dywidendy
14Zyski
15Pełne podstawowe wskaźniki
16Sprawozdania
17Właściciele instytucjonalni (13F)
18Aktywiści i właściciele 5%+
19Insiderzy spółki
20Posiadanie ETF-ów
21Konsensus
22Równi
23Wiadomości
26Moje wskaźniki
AORT Artivion, Inc. Common Stock
NYSE · Health Care · Wyświetl na SEC EDGAR ↗ zamknij Paź 2, 2026 10-K/10-Q Sie 7, 2026
$22,31
· % zakresu 52 tyg.
· powyżej minimum
· do maksimum
$19,1652tyg. minimum
$48,2552tyg. maksimum
Kapitalizacja Rynkowa (MRQ)
$1.12B
P/E (TTM)
-371.8
EPS (TTM)
$-0.06
Przychody (TTM)
$471M
Twoje odznaki
Zakres 52 tyg.
$19–$48
Ocena Analityków
BUY
Cena Docelowa
$42
P/E
-371.8
ROE
-0.73%
Marża Zysku Netto
-0.67%
Twój pasek odznak jest pusty — przypnij metrykę w dowolnym miejscu na tej stronie.
AORT Migawka akcji Cena, kapitalizacja rynkowa, P/E, EPS, ROE, zadłużenie/kapitał własny, zakres 52-tygodniowy
Cena
$22.31
Kapitalizacja Rynkowa (MRQ)
$1.12B
P/E (TTM)
-371.8
EPS (TTM)
$-0.06
Przychody (TTM)
$471M
ROE (TTM)
-0.73%
D/E Dług/Kapitał (MRQ)
0.8
Zakres 52 tyg.
$19–$48
AORT Wykres ceny akcji Dzienny OHLCV ze wskaźnikami technicznymi — przesuwaj, powiększaj i dostosowuj widok
zakres
kreski
Granularność słupków dostosowuje się do wybranego okresu — najedź kursorem na wykres, aby zobaczyć otwarcia/maksima/minima/zamknięcia dla danego słupka.
Podziały akcji
| Data ex-dywidendy | Podział | Typ |
|---|---|---|
| 28 grudnia 2000 | 3-for-2 | Naprzód |
| 1 lipca 1996 | 2-for-1 | Naprzód |
O Artivion, Inc. Common Stock Przegląd firmy z Wikipedii
Artivion, Inc. is a distributor of cryogenically preserved human tissues for cardiac and vascular transplant applications and develops medical devices. Among its products are human heart valves, which are treated to remove excess cellular material and antigens, and BioGlue surgical adhesive.
## History
Artivion was founded as CryoLife in Sarasota, Florida in 1984 by Steven Anderson and Robert McNally. Anderson acted as the company’s president and CEO from its founding. The company later moved from Sarasota to the Atlanta metropolitan area. In January 2022 the company changed its name to Artivion, Inc.
In 2000, CryoLife began offering a surgical adhesive called BioGlue used for sealing surgical lacerations under high pressure, such as in arteries.
In February 2008, the FDA gave CryoLife approval for a new kind of heart valve, made from human tissues, which was the first to remove cells from the transplant tissue as opposed to only cleaning the tissue. In giving the approval, the FDA said the new valve, called the CryoValve SynerGraft Pulmonary Valve, had less of a chance of rejection than previous valves.
In 2010, CryoLife acquired the rights to manufacture and distribute PerClot, an absorbable hemostatic powder used in surgery.
In January 2016, the company acquired On-X Life Technologies and its principal product, a mechanical heart valve called the On-X aortic valve replacement, for $130 million.
In October 2017, Artivion acquired JOTEC GmbH, a German-based developer of medical devices for aortic and peripheral vascular diseases, for €225 million. In September 2020, the company acquired Ascyrus Medical.
In 2021, the company received FDA premarket application approval of its PerClot absorbable hemostatic system, which comprised PerClot granules and a delivery system for surgical use. Baxter International agreed to buy PerClot from Artivion in 2021. In 2023, after final FDA approval of the product, the purchase was completed.
Źródło: Wikipedia (Angielski), CC BY-SA 4.0 · Zobacz w Wikipedii ↗
sektorHealth Care
branżaHealth Care
pracownicy1 800
krajUS
Wyniki 10-letnie Trendy przychodów, zysku netto, marż i EPS
Przychody$441M2016-12-31 → 2025-12-31
EPS$0.212016-12-31 → 2025-12-31
Wolny przepływ pieniężny$839.0K2016-12-31 → 2025-12-31
Marża netto-0.67%2016-12-31 → 2025-12-31
Wycena i wskaźniki
Wycena Wskaźniki P/E, P/S, P/B, EV/EBITDA — czy akcje są drogie, czy tanie?
| Wskaźnik | Trend 5-letni | AORT | średnia z 5 lat | Mediana porównawcza | Werdykt |
|---|---|---|---|---|---|
| P/E (TTM) | -371.8średnia z 5 lat ≈5.0 | ≈5.0 | · | · | |
| P/S (TTM) | 2.4średnia z 5 lat ≈3.0 | ≈3.0 | 3.9 | Niedowartościowany | |
| P/B (MRQ) | 2.5średnia z 5 lat ≈3.4 | ≈3.4 | 3.9 | Niedowartościowany | |
| EV / EBITDA | 22.5średnia z 5 lat ≈32.6 | ≈32.6 | · | · | |
| Cena / FCF (TTM) | -122.3średnia z 5 lat ≈554.3 | ≈554.3 | · | · | |
| Cena / Przepływy pieniężne (TTM) | 26.8średnia z 5 lat ≈-54.3 | ≈-54.3 | 38.0 | Zawyżona wycena | |
| EV / Revenue (EV / Przychody) | 2.9średnia z 5 lat ≈3.7 | ≈3.7 | · | · | |
| EV / FCF | 1508.1średnia z 5 lat ≈592.1 | ≈592.1 | · | · | |
| Cena / Wartość księgowa materialna (MRQ) | 3.8 | · | · | · |
Mediana porównawcza jest obliczana na znormalizowanej podstawie dla każdej metryki i może nie zawsze odpowiadać podstawie TTM/MRQ pokazanej dla tej akcji.
Rentowność Marże brutto, operacyjne i netto; ROE, ROA, ROIC
| Wskaźnik | Trend 5-letni | AORT | średnia z 5 lat | Mediana porównawcza | Werdykt |
|---|---|---|---|---|---|
| Marża brutto (TTM) | 64.4%średnia z 5 lat ≈64.8% | ≈64.8% | 64.0% | Zgodnie z | |
| Marża Operacyjna (TTM) | 4.4%średnia z 5 lat ≈4.8% | ≈4.8% | -7.6% | Zgodnie z | |
| Marża EBITDA (TTM) | 9.6%średnia z 5 lat ≈11.4% | ≈11.4% | -7.6% | Zgodnie z | |
| Marża przed opodatkowaniem (TTM) | 0.47%średnia z 5 lat ≈-2.9% | ≈-2.9% | -8.7% | Zgodnie z | |
| Marża Zysku Netto (TTM) | -0.67%średnia z 5 lat ≈-4.2% | ≈-4.2% | -9.5% | Zgodnie z | |
| ROA (TTM) | -0.33%średnia z 5 lat ≈-1.8% | ≈-1.8% | -20.2% | Najwyższa półka | |
| ROE (TTM) | -0.73%średnia z 5 lat ≈-5.1% | ≈-5.1% | -25.1% | Najwyższa półka | |
| ROIC | 3.4%średnia z 5 lat ≈3.8% | ≈3.8% | -31.3% | Najwyższa półka |
Zdrowie finansowe Dług, płynność, wypłacalność — siła bilansu
| Wskaźnik | Trend 5-letni | AORT | średnia z 5 lat | Mediana porównawcza | Werdykt |
|---|---|---|---|---|---|
| Dług / Kapitał Własny (MRQ) | 0.8średnia z 5 lat ≈1.0 | ≈1.0 | 0.6 | Wysokie zadłużenie | |
| Wskaźnik bieżący (MRQ) | 3.5średnia z 5 lat ≈4.6 | ≈4.6 | 5.6 | Niska płynność | |
| Quick Ratio (Wskaźnik Szybkości) | 1.5średnia z 5 lat ≈2.0 | ≈2.0 | 3.6 | Niska płynność | |
| Dług długoterminowy / Kapitał własny (MRQ) | 0.8średnia z 5 lat ≈1.0 | ≈1.0 | 0.6 | Wysokie zadłużenie |
Rozwój Wzrost przychodów, EPS i zysku netto: r/r, CAGR 3-letni, CAGR 5-letni
| Wskaźnik | Trend 5-letni | AORT | średnia z 5 lat | Mediana porównawcza | Werdykt |
|---|---|---|---|---|---|
| Revenue YoY (Przychody R/R) | 13.6%średnia z 5 lat ≈11.8% | ≈11.8% | · | · | |
| Revenue CAGR 3Y (Przychody CAGR 3L) | 12.0%średnia z 5 lat ≈11.0% | ≈11.0% | · | · | |
| Revenue CAGR 5Y (Przychody CAGR 5L) | 11.8% | · | · | · |
Efektywność kapitałowa Rotacja aktywów, rotacja zapasów, rotacja należności
| Wskaźnik | Trend 5-letni | AORT | średnia z 5 lat | Mediana porównawcza | Werdykt |
|---|---|---|---|---|---|
| Asset Turnover (Rotacja aktywów) | 0.5średnia z 5 lat ≈0.5 | ≈0.5 | 0.5 | Zgodnie z | |
| Inventory Turnover (Rotacja zapasów) | 1.8średnia z 5 lat ≈1.6 | ≈1.6 | 1.8 | Zgodnie z | |
| Receivables Turnover (Rotacja należności) | 5.2średnia z 5 lat ≈5.4 | ≈5.4 | 6.9 | Słaby | |
| Revenue / Employee (Przychody / pracownika) | ≈$245.2K | · | · | · |
wartość · ≈ średnia z 5 lat · mediana branżowa · werdykt względem mediany
Dywidendy Stopa dywidendy, wskaźnik wypłaty, historia dywidend, 5-letni CAGR
Zannualizowane wypłaty≈$0.12
| Data ex-dywidendy | Kwota | Waluta | Stopa zwrotu |
|---|---|---|---|
| Gru 9, 2015 | $0,03 | USD | ≈1.2% |
| Wrz 9, 2015 | $0,03 | USD | ≈1.2% |
| Cze 10, 2015 | $0,03 | USD | ≈1.1% |
| Mar 11, 2015 | $0,03 | USD | ≈1.2% |
| Gru 10, 2014 | $0,03 | USD | ≈1.1% |
| Wrz 10, 2014 | $0,03 | USD | ≈1.2% |
| Cze 11, 2014 | $0,03 | USD | ≈1.3% |
| Mar 12, 2014 | $0,03 | USD | ≈1.2% |
| Gru 11, 2013 | $0,03 | USD | ≈1.1% |
| Wrz 11, 2013 | $0,03 | USD | ≈1.7% |
| Cze 12, 2013 | $0,03 | USD | ≈1.7% |
| Mar 12, 2013 | $0,03 | USD | ≈1.2% |
| Gru 12, 2012 | $0,03 | USD | ≈0.83% |
| Wrz 12, 2012 | $0,03 | USD | ≈0.45% |
Historia zysków EPS faktyczny vs szacowany, zaskoczenie %, wskaźnik trafień, data następnych wyników
Średnie zaskoczenie
-518.1%
Następny raport
Lis 04, 2026
| Okres | Raport | EPS Actual | EPS Szacowany | Niespodzianka |
|---|---|---|---|---|
| 30 czerwca 2026 | Sie 5, 2026 | $-0.28 | $0.01 | -2845.1% |
| 31 marca 2026 | $0.03 | $0.05 | -40.1% | |
| 31 grudnia 2025 | $0.05 | $0.08 | -40.0% | |
| 30 września 2025 | $0.06 | $0.02 | 242.9% | |
| 30 czerwca 2025 | $0.08 | $-0.00 | — | |
| 31 marca 2025 | $-0.01 | $-0.12 | 91.7% |
Pełne podstawowe wskaźniki Wszystkie wskaźniki roczne — rachunek zysków i strat, bilans, przepływy pieniężne
Rachunek zysków i strat
| Wskaźnik | Trend | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $441M | $389M | $354M | $314M | $299M | $253M | $276M | $263M | $190M | $180M | $146M | $145M | |
| Cost of Revenue | $157M | $140M | $125M | $111M | $101M | $85M | $93M | $90M | $61M | $61M | $55M | $53M | |
| Gross Profit | $284M | $249M | $229M | $203M | $198M | $168M | $183M | $173M | $129M | $119M | $91M | $91M | |
| R&D Expense | $31M | $28M | $29M | $39M | $36M | $24M | $23M | $23M | $19M | $13M | $10M | $9M | |
| SG&A Expense | $226M | $181M | $209M | $157M | $170M | $141M | $143M | $141M | $101M | $92M | $75M | $74M | |
| Operating Expenses | $257M | $210M | $238M | $196M | $205M | $165M | $166M | $164M | $121M | $105M | $85M | $82M | |
| Operating Income | $34M | $39M | $6M | $6M | $8M | $2M | $17M | $9M | $8M | $22M | $5M | $9M | |
| Interest Expense | · | · | $25M | $18M | $17M | $17M | $15M | $16M | $5M | $3M | $62.0K | $175.0K | |
| Interest Income | $763.0K | $1M | $1M | $147.0K | $79.0K | $217.0K | $738.0K | $226.0K | $212.0K | $72.0K | $45.0K | $50.0K | |
| Other Non-op | $10M | $-10M | $-3M | $-3M | $-6M | $-3M | $-1M | $-141.0K | $260.0K | $-437.0K | $-484.0K | $-540.0K | |
| Pretax Income | $15M | $-8M | $-22M | $-15M | $-15M | $-17M | $2M | $-6M | $4M | $18M | $6M | $9M | |
| Income Tax | $5M | $6M | $9M | $4M | $7.0K | $-492.0K | $-76.0K | $-4M | $-143.0K | $8M | $2M | $1M | |
| Net Income | $10M | $-13M | $-31M | $-19M | $-15M | $-17M | $2M | $-3M | $4M | $11M | $4M | $7M | |
| EPS (Basic) | $0.22 | $-0.32 | $-0.75 | $-0.48 | $-0.38 | $-0.44 | $0.05 | $-0.08 | $0.11 | $0.33 | $0.14 | $0.26 | |
| EPS (Diluted) | $0.21 | $-0.32 | $-0.75 | $-0.48 | $-0.38 | $-0.44 | $0.05 | $-0.08 | $0.11 | $0.32 | $0.14 | $0.25 | |
| Shares (Basic) | 45,335,000 | 41,676,000 | 40,743,000 | 40,032,000 | 38,983,000 | 37,861,000 | 37,118,000 | 36,412,000 | 33,008,000 | 31,855,000 | 27,744,000 | 27,379,000 | |
| Shares (Diluted) | 47,162,000 | 41,676,000 | 40,743,000 | 40,032,000 | 38,983,000 | 37,861,000 | 37,860,000 | 36,412,000 | 34,163,000 | 32,822,000 | 28,542,000 | 28,313,000 | |
| EBITDA | $56M | $63M | $29M | $29M | $32M | $23M | $35M | $27M | $18M | $30M | · | $15M |
Bilans
| Wskaźnik | Trend | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash & Equivalents | $65M | $53M | $59M | $39M | $55M | $61M | $34M | $41M | $40M | $57M | $38M | $33M | |
| Receivables | $90M | $79M | $72M | $62M | $53M | $46M | $53M | $47M | $48M | $28M | $23M | $21M | |
| Inventory | $92M | $80M | $82M | $74M | $77M | $73M | $53M | $45M | $47M | $26M | $15M | $13M | |
| Prepaid Expense | $43M | $19M | $16M | $18M | $15M | $14M | $12M | $7M | $5M | $3M | $5M | $5M | |
| Current Assets | $358M | $290M | $281M | $247M | $248M | $235M | $187M | $179M | $179M | $147M | $110M | $106M | |
| PP&E (Net) | $65M | $36M | $38M | $39M | $38M | $33M | $32M | $31M | $34M | $19M | $11M | $12M | |
| PP&E (Gross) | · | · | · | $127M | $120M | $111M | $103M | $96M | $93M | $74M | $64M | $62M | |
| Accum. Depreciation | · | · | · | $88M | $82M | $78M | $71M | $65M | $60M | $55M | $53M | $50M | |
| Goodwill | $254M | $241M | $247M | $244M | $250M | $260M | $187M | $189M | $188M | $78M | $11M | $11M | |
| Intangibles | $124M | $128M | $143M | $151M | $167M | $186M | $115M | $118M | $130M | $1M | $1M | $2M | |
| Other Non-current Assets | $15M | $24M | $9M | $7M | $8M | $15M | $14M | $8M | $7M | $2M | $6M | $5M | |
| Total Assets | $885M | $789M | $792M | $763M | $793M | $789M | $606M | $571M | $590M | $316M | $181M | $176M | |
| Accounts Payable | $16M | $18M | $13M | $12M | $10M | $10M | $10M | $8M | $10M | $6M | $5M | $4M | |
| Accrued Liabilities | $16M | $12M | $10M | $12M | $8M | $7M | $7M | $7M | $12M | $5M | $3M | $3M | |
| Current Liabilities | $102M | $67M | $58M | $50M | $45M | $60M | $45M | $35M | $43M | $30M | $20M | $21M | |
| Capital Leases | $34M | $40M | $44M | $41M | $45M | $14M | $18M | $0 | $7M | $11.0K | · | · | |
| Deferred Tax | $24M | $20M | $22M | $24M | $29M | $35M | $26M | $27M | $30M | $7.0K | · | · | |
| Other Non-current Liabilities | $9M | $8M | $7M | $7M | $6M | $7M | $7M | $7M | $8M | $5M | $3M | $3M | |
| Total Liabilities | $437M | $513M | $511M | $478M | $492M | $461M | $320M | $296M | $313M | $107M | $26M | $27M | |
| Long-term Debt | $215M | $314M | $307M | $308M | $309M | $292M | $216M | $217M | $219M | $72M | · | · | |
| Total Debt | $215M | $314M | $307M | $308M | $309M | $292M | $216M | $217M | $219M | $72M | · | · | |
| Common Stock | $493.0K | $434.0K | $426.0K | $418.0K | $414.0K | $404.0K | $390.0K | $385.0K | $376.0K | $342.0K | $298.0K | $292.0K | |
| Retained Earnings | $-51M | $-61M | $-48M | $-17M | $2M | $20M | $37M | $35M | $38M | $34M | $23M | $23M | |
| Treasury Stock | $15M | $15M | $15M | $15M | $15M | $15M | $15M | $15M | $13M | $12M | $11M | $9M | |
| AOCI | $-3M | $-25M | $-12M | $-22M | $-10M | $7M | $-9M | $-6M | $2M | $-429.0K | $-76.0K | $-121.0K | |
| Stockholders' Equity | $448M | $276M | $282M | $284M | $301M | $329M | $286M | $275M | $277M | $209M | $155M | $149M | |
| Liabilities + Equity | $885M | $789M | $792M | $763M | $793M | $789M | $606M | $571M | $590M | $316M | $181M | $176M | |
| Shares Outstanding | 49,330,000 | 43,432,000 | 42,569,000 | 41,830,000 | 41,397,000 | 40,394,000 | 39,018,000 | 38,463,000 | 37,618,000 | 34,230,000 | 29,766,000 | 29,229,000 |
Przepływy pieniężne
| Wskaźnik | Trend | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| D&A | $22M | $24M | $23M | $22M | $24M | $21M | $18M | $18M | $10M | $8M | $6M | $6M | |
| Stock-based Comp | $24M | $14M | $14M | $12M | $11M | $7M | $9M | $6M | $7M | $6M | $5M | $3M | |
| Deferred Tax | $37.0K | $-2M | $-1M | $-885.0K | $-6M | $816.0K | $-2M | $-6M | $-1M | $3M | $1M | $173.0K | |
| Amort. of Intangibles | $14M | $16M | $15M | $15M | $17M | $14M | $11M | $11M | $5M | $4M | $2M | $2M | |
| Other Non-cash | $-17M | $-1M | $13M | $-20M | $-17M | $611.0K | $-11M | $-5M | $-8M | $-8M | · | $-9M | |
| Operating Cash Flow | $40M | $22M | $19M | $-5M | $-3M | $12M | $16M | $10M | $11M | $20M | $11M | $8M | |
| CapEx | $39M | $11M | $10M | $11M | $13M | $7M | $8M | $6M | $7M | $6M | $3M | $4M | |
| Investing Cash Flow | $-42M | $-28M | $-502.0K | $-11M | $6M | $-73M | $-24M | $-7M | $-171M | $-79M | $-4M | · | |
| Debt Issued | $0 | $184M | $0 | $0 | · | · | · | · | · | · | · | · | |
| Net Debt Issued | $-210.0K | $-28M | $-3M | · | · | · | · | · | · | · | · | · | |
| Stock Issued | $13M | $6M | $4M | $3M | $4M | $2M | $5M | $4M | $3M | $2M | $2M | $3M | |
| Stock Repurchased | · | · | · | · | · | · | · | · | · | · | · | $6M | |
| Net Stock Activity | $13M | $6M | $4M | $3M | $4M | $2M | $5M | $4M | $3M | $2M | · | $-3M | |
| Dividends Paid | · | · | · | · | · | · | · | · | · | · | $3M | $3M | |
| Financing Cash Flow | $11M | $2M | $865.0K | $-2M | $-12M | $94M | $-1M | $-3M | $143M | $73M | $-3M | · | |
| Net Change in Cash | $11M | $-5M | $20M | $-16M | $-7M | $28M | $-8M | $1M | $-17M | $14M | $4M | $-4M | |
| Taxes Paid | $3M | · | · | · | · | · | · | · | · | · | $145.0K | $3M | |
| Free Cash Flow | $839.0K | $11M | $11M | $-14M | $-16M | $5M | $8M | $4M | $4M | $14M | · | $4M | |
| Levered FCF | · | · | $-25M | $-38M | $-33M | $-11M | $-8M | $-3M | $-925.8K | $12M | · | · |
Rentowność
| Wskaźnik | Trend | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Gross Margin | 64.4% | 64.0% | 64.7% | 64.5% | 66.1% | 66.3% | 66.3% | 65.8% | 67.8% | 65.9% | · | 63.1% | |
| Operating Margin | 7.6% | 10.0% | 1.6% | 2.0% | 2.7% | 0.96% | 6.2% | 3.5% | 4.2% | 12.1% | · | 6.1% | |
| Net Margin | 2.2% | -3.4% | -8.7% | -6.1% | -5.0% | -6.6% | 0.62% | -1.1% | 1.9% | 6.0% | · | 5.1% | |
| Pretax Margin | 3.4% | -1.9% | -6.1% | -4.8% | -5.0% | -6.8% | 0.60% | -2.4% | 1.9% | 10.2% | · | 6.0% | |
| EBITDA Margin | 12.7% | 16.2% | 8.1% | 9.1% | 10.7% | 9.1% | 12.8% | 10.4% | 9.3% | 16.7% | · | 10.3% | |
| ROA | 1.2% | -1.7% | -4.0% | -2.5% | -1.9% | -2.4% | 0.29% | -0.49% | 0.82% | 4.3% | · | 4.2% | |
| ROE | 2.2% | -4.6% | -11.1% | -7.1% | -4.9% | -5.1% | 0.61% | -1.0% | 1.5% | 5.9% | · | 5.0% | |
| ROIC | 3.4% | 11.7% | 1.4% | 1.3% | 1.3% | 0.38% | 3.6% | 0.84% | 1.7% | 4.5% | · | 5.0% |
Płynność i wypłacalność
| Wskaźnik | Trend | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Current Ratio | 3.5 | 4.3 | 4.9 | 5.0 | 5.5 | 3.9 | 4.1 | 5.2 | 4.2 | 4.9 | · | 5.1 | |
| Quick Ratio | 1.5 | 2.0 | 2.3 | 2.0 | 2.4 | 1.8 | 1.9 | 2.6 | 2.0 | 2.8 | · | 2.6 | |
| Debt / Equity | 0.5 | 1.1 | 1.1 | 1.1 | 1.0 | 0.9 | 0.8 | 0.8 | 0.8 | 0.3 | · | · | |
| LT Debt / Equity | 0.5 | 1.1 | 1.1 | 1.1 | 1.0 | 0.9 | 0.8 | 0.8 | 0.8 | 0.3 | · | · | |
| Interest Coverage | · | · | 0.2 | 0.3 | 0.5 | 0.1 | 1.1 | 0.6 | 1.6 | 7.3 | · | · |
Efektywność
| Wskaźnik | Trend | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Asset Turnover | 0.5 | 0.5 | 0.5 | 0.4 | 0.4 | 0.4 | 0.5 | 0.5 | 0.4 | 0.7 | · | 0.8 | |
| Inventory Turnover | 1.8 | 1.7 | 1.6 | 1.5 | 1.4 | 1.4 | 1.9 | 1.9 | 1.7 | 3.0 | · | 4.7 | |
| Receivables Turnover | 5.2 | 5.1 | 5.3 | 5.5 | 6.0 | 5.1 | 5.5 | 5.6 | 5.0 | 7.0 | · | 7.4 |
Na akcję
| Wskaźnik | Trend | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Book Value / Share | $9.09 | $6.36 | $6.62 | $6.80 | $7.26 | $8.14 | $7.32 | $7.15 | $7.37 | $6.11 | · | $5.09 | |
| Revenue / Share | $9.36 | $9.32 | $8.69 | $7.84 | $7.67 | $6.69 | $7.30 | $7.22 | $5.55 | $5.50 | · | $5.11 | |
| Cash Flow / Share | $0.85 | $0.53 | $0.46 | $-0.13 | $-0.07 | $0.33 | $0.42 | $0.27 | $0.32 | $0.60 | · | $0.29 | |
| Cash / Share | $1.32 | $1.23 | $1.38 | $0.94 | $1.33 | $1.52 | $0.87 | $1.08 | $1.06 | $1.65 | · | $1.14 | |
| Dividend / Share | · | · | · | · | · | · | $0.00 | $0.00 | $0.00 | $0.00 | $0.12 | $0.12 | |
| Dividend Paid / Share | · | · | · | · | · | · | · | · | · | · | $0.12 | $0.12 | |
| EPS (TTM) | $0.21 | $-0.32 | $-0.75 | $-0.48 | $-0.38 | $-0.44 | $0.05 | $-0.08 | $0.11 | $0.32 | $0.14 | $0.25 |
Stopy Wzrostu
| Wskaźnik | Trend | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue YoY | 13.6% | 9.8% | 12.8% | 5.0% | 18.0% | · | · | · | · | · | · | · | |
| Revenue CAGR 3Y | 12.0% | 9.1% | 11.8% | · | · | · | · | · | · | · | · | · | |
| Revenue CAGR 5Y | 11.8% | · | · | · | · | · | · | · | · | · | · | · |
Wycena (TTM)
| Wskaźnik | Trend | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue TTM | $441M | $389M | $354M | $314M | $299M | $253M | $276M | $263M | $190M | $180M | $146M | $145M | |
| Net Income TTM | $10M | $-13M | $-31M | $-19M | $-15M | $-17M | $2M | $-3M | $4M | $11M | $4M | $7M | |
| Market Cap | $2.25B | $1.24B | $761M | $507M | $842M | $954M | $1.06B | $1.09B | $720M | $656M | · | $331M | |
| Enterprise Value | $2.40B | $1.50B | $1.01B | $776M | $1.10B | $1.18B | $1.24B | $1.27B | $899M | $670M | · | · | |
| P/E | 217.2 | -89.3 | -23.8 | -25.2 | -53.6 | -53.7 | 541.8 | -354.8 | 174.1 | 59.8 | 77.0 | 45.3 | |
| P/S | 5.1 | 3.2 | 2.2 | 1.6 | 2.8 | 3.8 | 3.8 | 4.2 | 3.8 | 3.6 | · | 2.3 | |
| P/B | 5.0 | 4.5 | 2.7 | 1.8 | 2.8 | 2.9 | 3.7 | 4.0 | 2.6 | 3.1 | · | 2.2 | |
| P / Tangible Book | 31.9 | · | · | · | · | · | · | · | · | · | · | · | |
| P / Cash Flow | 56.4 | 55.8 | 40.4 | -98.4 | -325.9 | 77.1 | 66.8 | 110.5 | 66.7 | 33.2 | · | 40.8 | |
| P / FCF | 2681.7 | 112.4 | 66.8 | -35.8 | -53.7 | 189.2 | 136.3 | 266.6 | 172.7 | 48.5 | · | 87.0 | |
| EV / EBITDA | 42.7 | 23.8 | 35.0 | 27.1 | 34.2 | 51.1 | 35.0 | 46.2 | 50.8 | 22.2 | · | · | |
| EV / FCF | 2860.7 | 136.0 | 88.6 | -54.7 | -70.0 | 234.9 | 159.8 | 309.4 | 215.6 | 49.6 | · | · | |
| EV / Revenue | 5.4 | 3.9 | 2.9 | 2.5 | 3.7 | 4.7 | 4.5 | 4.8 | 4.7 | 3.7 | · | · | |
| Dividend Yield | · | · | · | · | · | · | · | · | · | · | · | 0.99% | |
| Earnings Yield | 0.46% | -1.1% | -4.2% | -4.0% | -1.9% | -1.9% | 0.18% | -0.28% | 0.57% | 1.7% | 1.3% | 2.2% | |
| Payout Ratio | · | · | · | · | · | · | · | · | · | · | · | 45.0% | |
| Annual Payout | · | · | · | · | · | · | · | · | · | · | $3M | $3M |
Rachunek zysków i strat
| Wskaźnik | Trend | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $126M | $116M | $116M | $113M | $113M | $99M | $97M | $96M | $98M | $97M | $94M | $88M | $89M | $83M | $79M | $77M | |
| Cost of Revenue | $45M | $41M | $43M | $39M | $40M | $35M | $36M | $35M | $35M | $34M | $33M | $32M | $31M | $30M | $29M | $28M | |
| Gross Profit | $81M | $75M | $73M | $74M | $73M | $64M | $62M | $61M | $63M | $63M | $61M | $56M | $58M | $54M | $51M | $49M | |
| R&D Expense | $9M | $9M | $9M | $8M | $7M | $7M | $7M | $7M | $7M | $7M | $8M | $6M | $7M | $7M | $8M | $12M | |
| SG&A Expense | $80M | $61M | $57M | $57M | $58M | $55M | $51M | $50M | $49M | $31M | $50M | $51M | $57M | $50M | $38M | $41M | |
| Operating Expenses | $89M | $70M | $66M | $65M | $65M | $61M | $59M | $57M | $57M | $38M | $58M | $58M | $65M | $58M | $47M | $53M | |
| Operating Income | $-8M | $6M | $11M | $13M | $8M | $2M | $3M | $4M | $7M | $25M | $3M | $-1M | $8M | $-4M | $4M | $-4M | |
| Interest Expense | · | · | · | · | · | · | · | · | · | $8M | · | $7M | $6M | $6M | · | $5M | |
| Interest Income | $367.0K | $205.0K | $311.0K | $240.0K | $68.0K | $144.0K | $374.0K | $366.0K | $353.0K | $374.0K | $398.0K | $339.0K | $265.0K | $75.0K | $61.0K | $40.0K | |
| Other Non-op | $4M | $-286.0K | $1M | $399.0K | $5M | $3M | $-10M | $2M | $-983.0K | $-1M | $2M | $-2M | $-4M | $963.0K | $4M | $-4M | |
| Pretax Income | $-12M | $339.0K | $7M | $7M | $3M | $-2M | $-17M | $-1M | $-2M | $13M | $-591.0K | $-9M | $-3M | $-9M | $3M | $-13M | |
| Income Tax | $2M | $-1M | $4M | $554.0K | $2M | $-2M | $-119.0K | $1M | $-306.0K | $5M | $3M | $382.0K | $725.0K | $5M | $1M | $1M | |
| Net Income | $-14M | $1M | $2M | $7M | $1M | $-505.0K | $-16M | $-2M | $-2M | $8M | $-4M | $-10M | $-3M | $-14M | $2M | $-14M | |
| EPS (Basic) | $-0.28 | $0.03 | $0.06 | $0.14 | $0.03 | $-0.01 | $-0.40 | $-0.05 | $-0.05 | $0.18 | $-0.10 | $-0.24 | $-0.08 | $-0.33 | $0.05 | $-0.34 | |
| EPS (Diluted) | $-0.28 | $0.03 | $0.06 | $0.13 | $0.03 | $-0.01 | $-0.40 | $-0.05 | $-0.05 | $0.18 | $-0.10 | $-0.24 | $-0.08 | $-0.33 | $0.05 | $-0.34 | |
| Shares (Basic) | 48,541,000 | 48,074,000 | · | 47,233,000 | 44,296,000 | 42,232,000 | · | 41,844,000 | 41,683,000 | 41,290,000 | · | 40,881,000 | 40,755,000 | 40,432,000 | · | 40,115,000 | |
| Shares (Diluted) | 48,541,000 | 49,731,000 | · | 48,775,000 | 45,378,000 | 42,232,000 | · | 41,844,000 | 41,683,000 | 47,886,000 | · | 40,881,000 | 40,755,000 | 40,432,000 | · | 40,115,000 | |
| EBITDA | $-8M | $12M | · | $13M | $8M | $8M | · | $4M | $7M | $31M | · | $-1M | $8M | $2M | · | $-4M |
Bilans
| Wskaźnik | Trend | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash & Equivalents | $77M | $56M | $65M | $73M | $53M | $38M | $53M | $56M | $55M | $51M | · | $53M | $49M | $31M | · | $38M | |
| Receivables | $98M | $92M | $90M | $88M | $91M | $88M | $79M | $76M | $74M | $74M | · | $64M | $65M | $63M | · | $57M | |
| Inventory | $103M | $98M | $92M | $91M | $87M | $82M | $80M | $84M | $81M | $82M | · | $79M | $78M | $76M | · | $73M | |
| Prepaid Expense | $27M | $45M | $43M | $22M | $25M | $20M | $19M | $19M | $20M | $17M | · | $17M | $19M | $20M | · | $17M | |
| Current Assets | $371M | $358M | $358M | $337M | $319M | $287M | $290M | $288M | $285M | $277M | · | $267M | $264M | $241M | · | $238M | |
| PP&E (Net) | $74M | $68M | $65M | $41M | $40M | $38M | $36M | $38M | $37M | $38M | · | $37M | $38M | $39M | · | $36M | |
| Goodwill | $350M | $252M | $254M | $254M | $254M | $245M | $241M | $249M | $244M | $245M | $247M | $243M | $246M | $246M | $244M | $235M | |
| Intangibles | $149M | $120M | $124M | $126M | $129M | $128M | $128M | $135M | $135M | $138M | · | $143M | $147M | $150M | · | $148M | |
| Other Non-current Assets | $15M | $16M | $15M | $29M | $27M | $25M | $24M | $21M | $14M | $13M | · | $8M | $8M | $8M | · | $7M | |
| Total Assets | $1.07B | $883M | $885M | $858M | $838M | $791M | $789M | $803M | $790M | $784M | · | $775M | $778M | $757M | · | $743M | |
| Accounts Payable | $21M | $18M | $16M | $16M | $19M | $12M | $18M | $11M | $12M | $10M | · | $11M | $10M | $9M | · | $11M | |
| Accrued Liabilities | $16M | $17M | $16M | $12M | $11M | $12M | $12M | $16M | $16M | $16M | · | $10M | $10M | $10M | · | $10M | |
| Current Liabilities | $107M | $93M | $102M | $86M | $67M | $52M | $67M | $153M | $51M | $46M | · | $55M | $56M | $44M | · | $46M | |
| Capital Leases | $36M | $34M | $34M | $38M | $39M | $39M | $40M | $41M | $42M | $43M | · | $43M | $40M | $41M | · | $41M | |
| Deferred Tax | $26M | $28M | $24M | $22M | $23M | $22M | $20M | $19M | $22M | $22M | · | $20M | $19M | $24M | · | $34M | |
| Other Non-current Liabilities | $9M | $9M | $9M | $9M | $9M | $8M | $8M | $8M | $8M | $8M | · | $8M | $7M | $7M | · | $7M | |
| Total Liabilities | $626M | $433M | $437M | $419M | $418M | $497M | $513M | $498M | $494M | $489M | · | $503M | $495M | $477M | · | $488M | |
| Long-term Debt | $363M | $215M | $215M | $215M | $216M | $315M | $314M | $314M | $314M | $313M | · | $307M | $308M | $308M | · | $308M | |
| Total Debt | $363M | $215M | · | $215M | $216M | $315M | · | $314M | $314M | $313M | · | $307M | $308M | $308M | · | $308M | |
| Common Stock | $502.0K | $500.0K | $493.0K | $488.0K | $486.0K | $442.0K | $434.0K | $434.0K | $433.0K | $432.0K | · | $425.0K | $424.0K | $424.0K | · | $418.0K | |
| Retained Earnings | $-64M | $-50M | $-51M | $-54M | $-60M | $-62M | $-61M | $-45M | $-42M | $-40M | · | $-44M | $-34M | $-31M | · | $-19M | |
| Treasury Stock | $15M | $15M | $15M | $15M | $15M | $15M | $15M | $15M | $15M | $15M | · | $15M | $15M | $15M | · | $15M | |
| AOCI | $-12M | $-12M | $-3M | $-2M | $-3M | $-19M | $-25M | $-10M | $-16M | $-14M | · | $-21M | $-16M | $-18M | · | $-45M | |
| Stockholders' Equity | $446M | $450M | $448M | $439M | $420M | $294M | $276M | $305M | $295M | $295M | $282M | $272M | $283M | $280M | $284M | $255M | |
| Liabilities + Equity | $1.07B | $883M | $885M | $858M | $838M | $791M | $789M | $803M | $790M | $784M | · | $775M | $778M | $757M | · | $743M | |
| Shares Outstanding | 50,179,000 | 49,983,000 | 49,330,000 | 48,862,000 | 48,592,000 | 44,190,000 | 43,432,000 | 43,392,000 | · | · | 42,569,000 | 42,537,000 | 42,443,000 | 42,366,000 | 41,830,000 | 41,816,000 |
Przepływy pieniężne
| Wskaźnik | Trend | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| D&A | $7M | $6M | $6M | $6M | $6M | $5M | $6M | $6M | $6M | $6M | $6M | $6M | $6M | $6M | $5M | $6M | |
| Stock-based Comp | $8M | $8M | $4M | $6M | $6M | $8M | $3M | $4M | $4M | $3M | $4M | $3M | $4M | $3M | $3M | $3M | |
| Deferred Tax | · | · | · | · | · | · | $3M | · | · | · | $6M | · | · | · | · | · | |
| Amort. of Intangibles | $4M | $4M | $3M | $3M | $3M | $3M | $4M | $4M | $4M | $4M | $4M | $4M | $4M | $4M | $4M | $4M | |
| Other Non-cash | · | $-15M | · | · | · | $-30M | · | · | · | $-22M | · | · | · | $-2M | · | · | |
| Operating Cash Flow | $-1M | $1M | $20M | $22M | $15M | $-17M | $10M | $11M | $6M | $-5M | $11M | $7M | $7M | $-6M | $-217.0K | $4M | |
| CapEx | $11M | $8M | $28M | $5M | $3M | $4M | $1M | $4M | $3M | $4M | $3M | $3M | $3M | $3M | $4M | $3M | |
| Investing Cash Flow | $-129M | $-11M | $-31M | $-5M | $-3M | $-4M | $-11M | $-11M | $-3M | $-4M | $-3M | $-2M | $7M | $-3M | $-3M | $-3M | |
| Debt Issued | · | · | $0 | $0 | $0 | $0 | $-6M | $160M | $160M | $190M | $0 | $0 | $0 | $0 | · | · | |
| Net Debt Issued | · | $0 | · | · | · | $-66.0K | · | · | · | $-182M | · | · | · | · | · | · | |
| Stock Issued | $1M | $1M | $3M | $5M | $278.0K | $4M | $443.0K | $2M | $59.0K | $4M | $488.0K | $886.0K | $0 | $3M | $24.0K | $1M | |
| Net Stock Activity | · | $1M | · | · | · | $4M | · | · | · | $4M | · | · | · | $3M | · | · | |
| Financing Cash Flow | $152M | $463.0K | $2M | $2M | $3M | $4M | $174.0K | $1M | $-181.0K | $737.0K | $-2M | $-909.0K | $2M | $1M | $-859.0K | $252.0K | |
| Net Change in Cash | $22M | $-9M | $-9M | $20M | $16M | $-16M | $-3M | $1M | $4M | $-8M | $5M | $5M | $18M | $-9M | $2M | $-3M | |
| Free Cash Flow | · | $-7M | · | · | · | $-21M | · | · | · | $-9M | · | · | · | $-8M | · | · | |
| Levered FCF | · | · | · | · | · | · | · | · | · | $-14M | · | · | · | $-18M | · | · |
Rentowność
| Wskaźnik | Trend | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Gross Margin | 64.0% | 64.8% | · | 65.6% | 64.7% | 64.2% | · | 63.7% | 64.6% | 64.6% | · | 64.0% | 65.1% | 64.5% | · | 63.4% | |
| Operating Margin | -6.7% | 5.0% | · | 11.1% | 7.4% | 2.2% | · | 4.6% | 6.6% | 26.0% | · | -1.4% | 8.6% | -4.6% | · | -5.3% | |
| Net Margin | -10.7% | 1.2% | · | 5.7% | 1.2% | -0.51% | · | -2.4% | -2.2% | 7.7% | · | -11.2% | -3.8% | -16.3% | · | -17.8% | |
| Pretax Margin | -9.3% | 0.29% | · | 6.2% | 3.1% | -2.3% | · | -1.3% | -2.5% | 13.1% | · | -10.7% | -3.0% | -10.7% | · | -16.3% | |
| EBITDA Margin | -6.7% | 10.4% | · | 11.1% | 7.4% | 7.7% | · | 4.6% | 6.6% | 32.0% | · | -1.4% | 8.6% | 2.2% | · | -5.3% | |
| ROA | -1.4% | 0.17% | · | 0.78% | 0.17% | -0.06% | · | -0.29% | -0.27% | 0.98% | · | -1.3% | -0.44% | -1.8% | · | -1.8% | |
| ROE | -3.1% | 0.38% | · | 1.8% | 0.38% | -0.17% | · | -0.79% | -0.73% | 2.6% | · | -3.7% | -1.2% | -4.7% | · | -4.8% | |
| ROIC | -1.2% | 3.6% | · | 1.8% | 0.51% | 0.08% | · | 1.3% | 0.93% | 2.5% | · | -0.22% | 1.7% | -1.0% | · | -0.80% |
Płynność i wypłacalność
| Wskaźnik | Trend | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Current Ratio | 3.5 | 3.9 | · | 3.9 | 4.8 | 5.5 | · | 1.9 | 5.6 | 6.0 | · | 4.9 | 4.7 | 5.5 | · | 5.2 | |
| Quick Ratio | 1.6 | 1.6 | · | 1.9 | 2.2 | 2.4 | · | 0.9 | 2.5 | 2.7 | · | 2.1 | 2.0 | 2.1 | · | 2.1 | |
| Debt / Equity | 0.8 | 0.5 | · | 0.5 | 0.5 | 1.1 | · | 1.0 | 1.1 | 1.1 | · | 1.1 | 1.1 | 1.1 | · | 1.2 | |
| LT Debt / Equity | 0.8 | 0.5 | · | 0.5 | 0.5 | 1.1 | · | 0.7 | 1.1 | 1.1 | · | 1.1 | 1.1 | 1.1 | · | 1.2 | |
| Interest Coverage | · | · | · | · | · | · | · | · | · | 3.2 | · | -0.2 | 1.2 | -0.6 | · | -0.9 |
Efektywność
| Wskaźnik | Trend | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Asset Turnover | 0.1 | 0.1 | · | 0.1 | 0.1 | 0.1 | · | 0.1 | 0.1 | 0.1 | · | 0.1 | 0.1 | 0.1 | · | 0.1 | |
| Inventory Turnover | 0.5 | 0.5 | · | 0.4 | 0.5 | 0.4 | · | 0.4 | 0.4 | 0.4 | · | 0.4 | 0.4 | 0.4 | · | 0.4 | |
| Receivables Turnover | 1.3 | 1.3 | · | 1.4 | 1.4 | 1.2 | · | 1.4 | 1.4 | 1.4 | · | 1.4 | 1.5 | 1.4 | · | 1.4 |
Na akcję
| Wskaźnik | Trend | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Book Value / Share | $8.88 | $9.01 | · | $8.98 | $8.64 | $6.66 | · | $7.02 | · | · | · | $6.39 | $6.66 | $6.61 | · | $6.10 | |
| Revenue / Share | $2.59 | $2.34 | · | $2.32 | $2.49 | $2.34 | · | $2.29 | $2.35 | $2.03 | · | $2.15 | $2.19 | $2.06 | · | $1.92 | |
| Cash Flow / Share | · | $0.02 | · | · | · | $-0.40 | · | · | · | $-0.11 | · | · | · | $-0.15 | · | · | |
| Cash / Share | $1.54 | $1.12 | · | $1.50 | $1.10 | $0.85 | · | $1.29 | · | · | · | $1.26 | $1.15 | $0.73 | · | $0.90 | |
| EPS (TTM) | $-0.06 | $0.25 | · | $-0.25 | $-0.43 | $-0.51 | · | $-0.02 | $-0.21 | $-0.24 | · | $-0.60 | $-0.70 | $-0.73 | · | $-1.03 |
Wycena (TTM)
| Wskaźnik | Trend | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue TTM | $471M | $459M | · | $423M | $405M | $390M | · | $385M | $377M | $368M | · | $340M | $329M | $320M | · | $314M | |
| Net Income TTM | $-3M | $12M | · | $-9M | $-18M | $-21M | · | $-851.0K | $-8M | $-10M | · | $-25M | $-28M | $-29M | · | $-41M | |
| Market Cap | $1.13B | $1.83B | · | $2.07B | $1.51B | $1.09B | · | $1.16B | · | · | · | $645M | $730M | $555M | · | $579M | |
| Enterprise Value | $1.41B | $1.99B | · | $2.21B | $1.67B | $1.36B | · | $1.41B | · | · | · | $899M | $988M | $832M | · | $849M | |
| P/E | -374.5 | 146.5 | · | -169.4 | -72.3 | -48.2 | · | -1331.0 | -122.1 | -88.2 | · | -25.3 | -24.6 | -17.9 | · | -13.4 | |
| P/S | 2.4 | 4.0 | · | 4.9 | 3.7 | 2.8 | · | 3.0 | · | · | · | 1.9 | 2.2 | 1.7 | · | 1.8 | |
| P/B | 2.5 | 4.1 | · | 4.7 | 3.6 | 3.7 | · | 3.8 | · | · | · | 2.4 | 2.6 | 2.0 | · | 2.3 | |
| P / Tangible Book | · | 23.2 | · | 35.5 | 41.0 | · | · | · | · | · | · | · | · | · | · | · | |
| P / Cash Flow | · | 1586.1 | · | · | · | -64.1 | · | · | · | · | · | · | · | -90.2 | · | · | |
| EV / Revenue | 3.0 | 4.3 | · | 5.2 | 4.1 | 3.5 | · | 3.7 | · | · | · | 2.6 | 3.0 | 2.6 | · | 2.7 | |
| Dividend Yield | 0.30% | 0.19% | · | 0.16% | 0.23% | 0.31% | · | 0.30% | · | · | · | 0.53% | 0.47% | 0.61% | · | 0.59% | |
| Earnings Yield | -0.27% | 0.68% | · | -0.59% | -1.4% | -2.1% | · | -0.08% | -0.82% | -1.1% | · | -4.0% | -4.1% | -5.6% | · | -7.4% | |
| Annual Payout | $3M | $3M | · | $3M | $3M | $3M | · | $3M | $3M | $3M | · | $3M | $3M | $3M | · | $3M |
Najnowszy okres po lewej · wartości null pokazane jako ·
Sprawozdania finansowe Rachunek zysków i strat, bilans, przepływy pieniężne — roczne, ostatnie 5 lat
| Wskaźnik | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|---|
| Przychody | $441M | $389M | $354M | $314M | $299M |
| Marża Brutto % | 64.4% | 64.0% | 64.7% | 64.5% | 66.1% |
| Marża Operacyjna % | 7.6% | 10.0% | 1.6% | 2.0% | 2.7% |
| Zysk netto | $10M | $-13M | $-31M | $-19M | $-15M |
| Rozwodniony EPS | $0.21 | $-0.32 | $-0.75 | $-0.48 | $-0.38 |
| Wskaźnik | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|---|
| Dług / Kapitał Własny | 0.5 | 1.1 | 1.1 | 1.1 | 1.0 |
| Wskaźnik bieżący | 3.5 | 4.3 | 4.9 | 5.0 | 5.5 |
| Wskaźnik Szybkości | 1.5 | 2.0 | 2.3 | 2.0 | 2.4 |
| Wskaźnik | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|---|
| Wolny przepływ pieniężny | $839.0K | $11M | $11M | $-14M | $-16M |
Właściciele instytucjonalni (13F) 212 emitentów · $1.2B łącznie · Na dzień 30 września 2026
Instytucje, które zgłaszają posiadanie tych akcji w swoich kwartalnych zgłoszeniach SEC Form 13F. Tylko pozycje długie; pojedynczy zgłaszający może pojawić się dwukrotnie dla oddzielnych transz opcji. Duże przeciwstawne pozycje put/call zazwyczaj odzwierciedlają działalność market-makingową lub zabezpieczone zapasy, a nie przekonanie kierunkowe.
Posiadacze
212
Wartość posiadanych akcji
$1.2B
Nowe pozycje
34
Zamknięte pozycje
65
Aktywność instytucjonalna — Q2 2026 vs poprzedni kwartał
| Nowe pozycje | Zamknięte pozycje | Zwiększone | Zmniejszony | Zmiana liczby akcji netto |
|---|---|---|---|---|
| 34 (-7 vs poprzedni kw.) | 65 (+29 vs poprzedni kw.) | 81 (-12 vs poprzedni kw.) | 56 (-7 vs poprzedni kw.) | +2.0M |
Porównano z Q1 2026. Zgłoszenia SEC Form 13F są wymagane w ciągu 45 dni od końca kwartału plus krótki bufor dla spóźnionych zgłoszeń — kwartały mieszczące się jeszcze w tym terminie są pomijane na rzecz ostatniej w pełni zgłoszonej pary.
| Instytucja | Wartość | Akcje | % z śledzonych 13F | Typ |
|---|---|---|---|---|
| BlackRock, Inc. | $149 965 153 | 6 674 017 | 12,78% | Akcje |
| VANGUARD GROUP INC | $144 587 760 | 3 170 089 | 12,33% | Akcje |
| NOMURA ASSET MANAGEMENT INTERNATIONAL INC. | $71 566 000 | 3 184 974 | 6,10% | Akcje |
| MORGAN STANLEY | $57 477 400 | 2 557 961 | 4,90% | Akcje |
| Juniper Investment Company, LLC | $45 386 816 | 2 019 885 | 3,87% | Akcje |
| VANGUARD CAPITAL MANAGEMENT LLC | $45 043 789 | 2 004 619 | 3,84% | Akcje |
| FMR LLC | $44 119 203 | 1 963 471 | 3,76% | Akcje |
| STATE STREET CORP | $41 750 406 | 1 858 051 | 3,56% | Akcje |
| Ophir Asset Management Pty Ltd | $40 446 180 | 1 800 008 | 3,45% | Akcje |
| PERCEPTIVE ADVISORS LLC | $39 036 906 | 1 737 290 | 3,33% | Akcje |
| Conestoga Capital Advisors, LLC | $36 484 539 | 1 623 700 | 3,11% | Akcje |
| WELLINGTON MANAGEMENT GROUP LLP | $28 318 470 | 1 260 279 | 2,41% | Akcje |
| GEODE CAPITAL MANAGEMENT, LLC | $25 043 403 | 1 114 297 | 2,13% | Akcje |
| SILVERCREST ASSET MANAGEMENT GROUP LLC | $23 011 325 | 1 024 091 | 1,96% | Akcje |
| VANGUARD PORTFOLIO MANAGEMENT LLC | $22 205 281 | 988 219 | 1,89% | Akcje |
| DIMENSIONAL FUND ADVISORS LP | $21 300 127 | 947 941 | 1,82% | Akcje |
| CITADEL ADVISORS LLC | $18 596 037 | 827 594 | 1,59% | Akcje |
| YARGER WEALTH STRATEGIES, LLC | $15 278 432 | 634 223 | 1,30% | Akcje |
| ROYCE & ASSOCIATES LP | $14 364 667 | 639 282 | 1,22% | Akcje |
| NORTHERN TRUST CORP | $12 370 454 | 550 532 | 1,05% | Akcje |
| BANK OF AMERICA CORP /DE/ | $11 716 689 | 521 437 | 1,00% | Akcje |
| Qube Research & Technologies Ltd | $10 704 820 | 476 405 | 0,91% | Akcje |
| FRED ALGER MANAGEMENT, LLC | $10 406 104 | 463 111 | 0,89% | Akcje |
| UBS Group AG | $10 210 390 | 454 401 | 0,87% | Akcje |
| TWO SIGMA ADVISERS, LP | $9 974 907 | 218 700 | 0,85% | Akcje |
| Invesco Ltd. | $9 956 839 | 443 117 | 0,85% | Akcje |
| GOLDMAN SACHS GROUP INC | $9 857 903 | 438 714 | 0,84% | Akcje |
| D. E. Shaw & Co., Inc. | $9 846 714 | 438 216 | 0,84% | Akcje |
| CHARLES SCHWAB INVESTMENT MANAGEMENT INC | $9 183 579 | 408 704 | 0,78% | Akcje |
| Toroso Investments, LLC | $9 018 146 | 197 723 | 0,77% | Akcje |
| Soleus Capital Management, L.P. | $8 718 360 | 388 000 | 0,74% | Akcje |
| TWO SIGMA INVESTMENTS, LP | $8 702 159 | 387 279 | 0,74% | Akcje |
| Balyasny Asset Management L.P. | $8 584 686 | 382 051 | 0,73% | Akcje |
| First Eagle Investment Management, LLC | $7 787 496 | 346 573 | 0,66% | Akcje |
| VANGUARD FIDUCIARY TRUST CO | $6 978 103 | 310 552 | 0,59% | Akcje |
| KENNEDY CAPITAL MANAGEMENT LLC | $6 611 371 | 294 231 | 0,56% | Akcje |
| Legal & General Group Plc | $5 826 427 | 259 298 | 0,50% | Akcje |
| WASATCH ADVISORS LP | $5 726 929 | 156 388 | 0,49% | Akcje |
| PRINCIPAL FINANCIAL GROUP INC | $5 705 178 | 253 902 | 0,49% | Akcje |
| Bank of New York Mellon Corp | $5 671 109 | 252 386 | 0,48% | Akcje |
| Quantinno Capital Management LP | $4 497 191 | 200 142 | 0,38% | Akcje |
| AMERIPRISE FINANCIAL INC | $4 348 978 | 193 546 | 0,37% | Akcje |
| FIFTH THIRD BANCORP | $4 170 912 | 185 621 | 0,36% | Akcje |
| ORBIMED ADVISORS LLC | $3 932 250 | 175 000 | 0,34% | Akcje |
| Corient Private Wealth LP | $3 580 552 | 159 348 | 0,31% | Akcje |
| UBS AM, a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC | $3 324 253 | 90 777 | 0,28% | Akcje |
| Public Sector Pension Investment Board | $3 298 304 | 146 787 | 0,28% | Akcje |
| Parkman Healthcare Partners LLC | $3 121 982 | 138 940 | 0,27% | Akcje |
| Universal- Beteiligungs- und Servicegesellschaft mbH | $2 879 149 | 128 133 | 0,25% | Akcje |
| VOLORIDGE INVESTMENT MANAGEMENT, LLC | $2 857 263 | 127 159 | 0,24% | Akcje |
Aktywiści i właściciele 5%+ 5 akcji
Inwestorzy, którzy złożyli SEC Schedule 13D — posiadanie beneficjentów powyżej 5% z zamiarem wpływania na emitenta (udziały aktywistów, kampanie zarządu, M&A). Każdy wiersz pokazuje najnowszy znany stan pozycji tego zgłaszającego.
| Zgłaszający | Złożono | Udział | Status | Cel | Zgłoszenie |
|---|---|---|---|---|---|
| Juniper Targeted Opportunity Fund, L.P., Juniper HF Investors II, LLC, Juniper Targeted Opportunities, L.P., Juniper Targeted Opportunity Investors, LLC, Juniper Multi-Strategy Fund, L.P., Juniper HF Investors, LLC, Juniper Investment Company, LLC, Alexis P. Michas, John A. Bartholdson ×2 zgłoszenia | 12 sierpnia 2025 | 4,00% | Aneks | · | SEC |
| CryoLife, Inc., CL Falcon, Inc. | 11 maja 2011 | · | Pierwotne zgłoszenie | M&A / sprzedaż | SEC |
| Michael A. Roth and Brian J. Stark, as joint filers pursuant to Rule 13d-1(k) | 10 lipca 2007 | · | Pierwotne zgłoszenie | · | SEC |
| Niezgłoszona osoba raportująca, Niezgłoszona osoba raportująca, Niezgłoszona osoba raportująca, Niezgłoszona osoba raportująca, Niezgłoszona osoba raportująca, Niezgłoszona osoba raportująca, Niezgłoszona osoba raportująca | 2 grudnia 2005 | · | Pierwotne zgłoszenie | Inwestycja pasywna | SEC |
| Niezgłoszona osoba raportująca | 18 marca 2005 | · | Pierwotne zgłoszenie | Inwestycja pasywna | SEC |
Purpose is an automated classification of the filer's own stated purpose (SEC Item 4) — not investment advice. "—" means no clear purpose was stated or the text could not be classified.
Insiderzy spółki 49 insiderów · 30 dyrektorzy generalni · 15 dyrektorzy
| Insider | Rola | Ostatnia aktywność | Posiadane akcje | Kupna 12m | Sprzedaże 12m | Netto 12m |
|---|---|---|---|---|---|---|
| James P Mackin | President & CEO | 19 sierpnia 2026 S | 877 275 | 0 | 9 | $-9 722 946 |
| Lance A Berry | EVP, COO, CFO & Treasurer | 14 sierpnia 2026 S | 210 112 | 0 | 5 | $-803 205 |
| David Ashley Lee | Executive VP, COO & CFO | 2 marca 2023 S | 347 217 | 0 | 0 | $0 |
| Andrew M Green | SVP, Regulatory and Quality | 10 września 2026 S | 40 160 | 0 | 6 | $-1 431 215 |
| Jean F Holloway | SVP, General Counsel | 12 sierpnia 2026 S | 184 118 | 0 | 13 | $-2 537 794 |
| Marshall S. Stanton | SVP, Clinical & MD Affair | 3 marca 2026 S | 60 097 | 0 | 13 | $-3 426 956 |
| John E Davis | Chief Commercial Officer | 3 marca 2026 S | 230 794 | 0 | 9 | $-1 745 924 |
| Amy Horton | VP, Chief Accounting Officer | 3 marca 2026 S | 139 088 | 0 | 8 | $-870 080 |
| Matthew A Getz | VP, Human Resources | 16 sierpnia 2024 S | 34 116 | 0 | 0 | $0 |
| Florian Tyrs | VP, Global Operations | 27 lutego 2024 S | 21 558 | 0 | 0 | $0 |
| Rochelle L. Maney | VP, Quality | 26 lutego 2024 S | 44 518 | 0 | 0 | $0 |
| Robert C Thomson | VP Research & Development | 23 lutego 2024 A | 13 291 | 0 | 0 | $0 |
| Dennis B Maier | SVP, Operations | 6 czerwca 2023 S | 34 724 | 0 | 0 | $0 |
| Franz Peter Barthold | VP, Research & Development | 8 listopada 2022 A | 32 516 | 0 | 0 | $0 |
| Scott B Capps | VP, Clinical Research | 12 marca 2021 F | 153 203 | 0 | 0 | $0 |
| James M Mcdermid | SVP, CHRO | 14 marca 2019 F | 30 806 | 0 | 0 | $0 |
| Sherry M Saurini | VP, Quality | 14 marca 2019 F | 25 084 | 0 | 0 | $0 |
| William Robert Matthews | Senior VP, Operations, Quality | 5 marca 2018 F | 39 883 | 0 | 0 | $0 |
| David C Gale | VP, Research & Development | 16 listopada 2017 M | 77 135 | 0 | 0 | $0 |
| Steven G Anderson | Former Executive Chairman | 9 kwietnia 2015 F | 1 271 846 | 0 | 0 | $0 |
| Bruce G. Anderson | VP, US Sales &Global Marketing | 7 marca 2015 F | 42 106 | 0 | 0 | $0 |
| FRONK DAVID | VP, Regulatory Affairs | 7 marca 2015 F | 110 559 | 0 | 0 | $0 |
| David P. Lang | VP, Int'l Sales & Marketing | 26 lutego 2015 A | 73 441 | 0 | 0 | $0 |
| Jeffrey W Burris | Vice President & Gen. Counsel | 15 sierpnia 2014 M | 95 221 | 0 | 0 | $0 |
| Gerald B Seery | Sr. VP, Sales and Marketing | 30 listopada 2012 S | 71 999 | 0 | 0 | $0 |
| Albert E Heacox | Sr. VP Research and Devl | 31 grudnia 2011 F | 110 144 | 0 | 0 | $0 |
| Philip A Theodore | VP, General Counsel | 4 września 2007 A | 23 100 | 0 | 0 | $0 |
| Sidney B Ashmore | Vice President of Marketing | 18 stycznia 2006 M | 42 728 | 0 | 0 | $0 |
| Kirby S Black | Sr. Vice President, R&D | 21 września 2004 M | 55 131 | 0 | 0 | $0 |
| Vander James C Wyk | VP - Product Integrity | 14 września 2004 M | 36 165 | 0 | 0 | $0 |
| Anthony B. Semedo | Dyrektor | 2 czerwca 2026 J | 6 325 | 0 | 0 | $0 |
| Elizabeth A Hoff | Dyrektor | 18 maja 2026 A | 34 765 | 0 | 1 | $-189 420 |
| Marna P Borgstrom | Dyrektor | 18 maja 2026 A | 56 664 | 0 | 0 | $0 |
| Jon W Salveson | Dyrektor | 18 maja 2026 A | 137 416 | 0 | 0 | $0 |
| Jeffrey H Burbank | Dyrektor | 18 maja 2026 A | 61 372 | 0 | 0 | $0 |
| Daniel J Bevevino | Dyrektor | 18 maja 2026 A | 157 637 | 0 | 0 | $0 |
| Bullock James | Dyrektor | 18 maja 2026 A | 76 223 | 0 | 0 | $0 |
| Thomas F Ackerman | Dyrektor | 18 maja 2026 A | 157 472 | 0 | 0 | $0 |
| Harvey Morgan | Dyrektor | 30 sierpnia 2021 G | 46 342 | 0 | 0 | $0 |
| Ronald D Mccall | Dyrektor | 25 sierpnia 2021 S | 121 768 | 0 | 0 | $0 |
| Elkins C Ronald | Dyrektor | 5 września 2018 S | 64 843 | 0 | 0 | $0 |
| James Benson | Dyrektor | 2 października 2017 S | 54 086 | 0 | 0 | $0 |
| John M Cook | Dyrektor | 9 czerwca 2009 M | 85 000 | 0 | 0 | $0 |
| LACY VIRGINIA C | Dyrektor | 24 kwietnia 2007 S | 255 280 | 0 | 0 | $0 |
| VAN DYNE BRUCE J MD | Dyrektor | 1 sierpnia 2006 A | 12 800 | 0 | 0 | $0 |
| OSS CAPITAL MANAGEMENT | Posiadacz 10% | 31 maja 2007 S | 1 918 000 | 0 | 0 | $0 |
| Michael S Simpson | · | 5 marca 2021 F | 33 698 | 0 | 0 | $0 |
| Thomas J Bogenschuetz | · | 5 maja 2020 A | 23 451 | 0 | 0 | $0 |
| Thomas J Lynch | · | 2 listopada 2004 A | 5 000 | 0 | 0 | $0 |
Insiderzy z zgłoszeń SEC Form 3/4/5; netto = tylko otwarty rynek P/S
Posiadanie ETF-ów Posiadane przez 36 funduszy ETF
Waga odzwierciedla wyłącznie bezpośrednie udziały kapitałowe (N-PORT); fundusze oparte na dźwigni lub instrumentach pochodnych mogą posiadać dodatkowe ekspozycje na swapy, które nie są pokazane.
| Fundusz | Waga | Jednostki | Na dzień | Źródło |
|---|---|---|---|---|
| HTEC · EXCHANGE TRADED CONCEPTS TRUST | 1,64% | 42 246 NS | 31 lipca 2026 | N-PORT |
| PSCH · Invesco Exchange-Traded Fund Trust … | 0,59% | 46 432 SH | 2 października 2026 | Dziennie |
| RZG · Invesco Exchange-Traded Fund Trust | 0,40% | 21 951 SH | 2 października 2026 | Dziennie |
| EBIT · Harbor ETF Trust | 0,25% | 1 133 NS | 31 lipca 2026 | N-PORT |
| ESSC · Strategy Shares | 0,17% | 2 304 NS | 31 lipca 2026 | N-PORT |
| IHI · iShares Trust | 0,16% | 203 954 SH | 11 września 2026 | Dziennie |
| VIOG · VANGUARD ADMIRAL FUNDS | 0,10% | 50 848 SH | 19 sierpnia 2026 | Dziennie |
| IWO · iShares Trust | 0,07% | 429 440 SH | 11 września 2026 | Dziennie |
| VTWG · VANGUARD SCOTTSDALE FUNDS | 0,06% | 49 054 SH | 19 sierpnia 2026 | Dziennie |
| VIOO · VANGUARD ADMIRAL FUNDS | 0,05% | 148 966 SH | 19 sierpnia 2026 | Dziennie |
| RSSL · Global X Funds | 0,04% | 21 860 NS | 31 lipca 2026 | N-PORT |
| ISCG · iShares Trust | 0,04% | 14 453 SH | 11 września 2026 | Dziennie |
| IWM · iShares Trust | 0,04% | 1 164 969 SH | 11 września 2026 | Dziennie |
| VTWO · VANGUARD SCOTTSDALE FUNDS | 0,03% | 263 046 SH | 19 sierpnia 2026 | Dziennie |
| RWJ · Invesco Exchange-Traded Fund Trust … | 0,03% | 23 979 SH | 2 października 2026 | Dziennie |
| PRFZ · Invesco Exchange-Traded Fund Trust | 0,03% | 30 302 SH | 2 października 2026 | Dziennie |
| DFAS · Dimensional ETF Trust | 0,02% | 124 676 NS | 31 lipca 2026 | N-PORT |
| FHLC · FIDELITY COVINGTON TRUST | 0,02% | 20 435 NS | 31 lipca 2026 | N-PORT |
| VXF · VANGUARD INDEX FUNDS | 0,01% | 495 296 SH | 19 sierpnia 2026 | Dziennie |
| VHT · VANGUARD WORLD FUND | 0,01% | 127 662 SH | 19 sierpnia 2026 | Dziennie |
| WSML · iShares Trust | 0,01% | 2 287 SH | 11 września 2026 | Dziennie |
| DXUV · Dimensional ETF Trust | 0,01% | 1 400 NS | 31 lipca 2026 | N-PORT |
| DFAC · Dimensional ETF Trust | 0,01% | 90 038 NS | 31 lipca 2026 | N-PORT |
| TILT · FlexShares Trust | 0,00% | 3 634 NS | 31 lipca 2026 | N-PORT |
| DCOR · Dimensional ETF Trust | 0,00% | 4 761 NS | 31 lipca 2026 | N-PORT |
| DFAU · Dimensional ETF Trust | 0,00% | 9 530 NS | 31 lipca 2026 | N-PORT |
| DFUS · Dimensional ETF Trust | 0,00% | 13 831 NS | 31 lipca 2026 | N-PORT |
| ITOT · iShares Trust | 0,00% | 61 878 SH | 11 września 2026 | Dziennie |
| IWV · iShares Trust | 0,00% | 10 858 SH | 11 września 2026 | Dziennie |
| DFAT · Dimensional ETF Trust | 0,00% | 2 692 NS | 31 lipca 2026 | N-PORT |
| VTI · VANGUARD INDEX FUNDS | 0,00% | 1 463 340 SH | 19 sierpnia 2026 | Dziennie |
| VTHR · VANGUARD SCOTTSDALE FUNDS | 0,00% | 3 652 SH | 19 sierpnia 2026 | Dziennie |
| IJR · iShares Trust | · | 2 603 782 SH | 10 września 2026 | Dziennie |
| IJT · iShares Trust | · | 403 685 SH | 9 września 2026 | Dziennie |
| XJR · iShares Trust | · | 5 899 SH | 2 września 2026 | Dziennie |
| ISCB · iShares Trust | · | 2 111 SH | 11 września 2026 | Dziennie |
AORT Konsensus analityków Bycze i niedźwiedzie opinie analityków, 12-miesięczny cel cenowy, potencjał wzrostu
ocena · 14 analityków
KUP
Średni cel
$42.00
+88,3%
5 35,7%
Mocne kupno
8 57,1%
Kup
1 7,1%
Trzymaj
0 0,0%
Sprzedaj
0 0,0%
Mocna sprzedaż
12-miesięczny cel cenowy
8 analityków · 2026-09-29Średnia cel $42.15 +88,9%
← Poniżej wszystkich celów
Aktualna cena $22.31
Niski$38.00
Średnia$42.15
Wysoki$48.00
Porównanie z porównywalnymi firmami (podbranża GICS) Kluczowe metryki w porównaniu do konkurentów z sektora
Podstawa R/R, ceny według zamknięcia z ostatniego końca roku obrotowego każdej spółki.
| Ticker | Kapitalizacja Rynkowa | P/E | Przychody r/r | Marża Netto | ROE | Marża brutto |
|---|---|---|---|---|---|---|
| AORT | $2.25B | 217.2 | 13.6% | 2.2% | 2.2% | 64.4% |
| IRMD | $1.24B | 55.6 | 14.4% | 26.8% | 23.8% | 76.8% |
| IART | · | -1.8 | 1.5% | -31.6% | -49.6% | · |
| ENOV | $1.52B | -1.3 | 6.7% | -52.7% | -58.5% | 59.8% |
| BBNX | $1.35B | -16.8 | 53.9% | -73.0% | -24.9% | 55.4% |
| PRCT | $1.77B | -18.3 | 37.2% | -31.0% | -25.4% | 63.7% |
| CBLL | $822M | -15.0 | 36.1% | -60.0% | -32.6% | 87.9% |
| SIBN | $861M | -44.8 | 20.2% | -9.4% | -10.9% | 79.6% |
| VREX | $498M | -7.0 | 4.1% | -8.3% | -14.0% | 34.4% |
| ABT | $250.18B | 33.7 | 5.7% | 14.7% | 13.1% | · |
Najnowsze wiadomości Najnowsze nagłówki wspominające o tej firmie
Moje wskaźniki Twoja osobista lista obserwowanych — wybrane wiersze z Pełnych Fundamentów
Wybierz wskaźniki, które są dla Ciebie ważne — kliknij + obok dowolnego wiersza w sekcji Pełne dane fundamentalne powyżej.
Twój wybór został zapisany i będzie Ci towarzyszył we wszystkich tickerach.
Źródło: SEC 10-Q złożone Sie 7, 2026